Lurasidone (Latuda) Gets FDA Nod for Bipolar Depression in Kids

Share this post

Lurasidone is now indicated for the treatment of major depressive episodes associated with bipolar I disorder in children and adolescents aged 10 to 17 years.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply